Finance Committee Chair's Highlight Report to Trust Board

Subject:	Finance Committee (FC) Report			Date:	6 February 2025
Prepared By:	Graham Ward – FC Chair				
Approved By:					
Presented By:	Graham Ward – FC Chair				
Purpose:					
To provide an ov	rerview of the key discussion items from the Finance	Co	mmittee meetings of 1	7 December	2024 and 28 January 2025.
Matters of Con	cern or Key Risks Escalated for Noting / Action		-		ned / Work Underway
 <u>Workforce</u> (to NOTE) – The Band 2 to 3 Review is likely to have an initial cost of £2.2M (which is being provided for) and an ongoing impact of up to £750K per annum. <u>Workforce</u> (for ACTION) – There is potential for further material changes financially which may arise from a review of Bands 4 to 9. This is being pushed for local resolution, but the recommendation is for Board to escalate and request national intervention. 		 Committee in Febru Board at its March <u>Surgery Division</u> – 3 development. <u>Procurement</u> – Furt 	Support to be given on strategic options ner work to be undertaken on reviewing ance contracts to identify potential for		
the Trust has £1.9M). The f deficit £2.2M	ncial Position (to NOTE) – At the end of Month 9 a deficit of £7.3M (an adverse variance to plan of forecast outturn for the year has a risk range from a at best to a worst-case position of £14.7M. It is grip and control effort continues and this is carried				
· · ·	FE) – Cash continues to be a major issue with all support requests having been turned down.				
savings the s	nning (to NOTE) – due to the low current recurrent tarting point prior to the 2025/26 FIP programme is f in excess of £60M (11% of costs).				

Positive Assurances to Provide <u>Surgery Division</u> – Noted deep dive presentation in December and concern over Anaesthetic Consultant vacancies (35%), plus forecast overspend of £2.1M for 2024/25. Clinical Support Therapies & Outpatients Division – Noted deep	 Decisions Made (include BAF review outcomes) Aseptic Dispensing Unit – Business case approved at December meeting ICB IT Equipment Purchase – Business case agreed to be recommended to Board for approval subject to confirmation of
dive presentation in January and excellent performance on their FIP programme together with the reductions in DNA rates down to 6% (from a peak of 8.1% in Oct 2023) and planned at 5% by March 2025. <u>NHIS Performance</u> – Noted that forecast expenditure and income had been reduced to support savings requirements at all customers. Request to review opportunity for making some of the reductions recurrent. <u>Digital Landscape</u> – Received a helpful paper outlining the current cost of the Trust's digital infrastructure (hardware and software), together with a predicted position in 5 years incorporating known changes. Agreed that this would act as a good base position to work from for any future business cases. <u>Procurement Forward View</u> – Received and noted.	 funding from the ICB. <u>BAF</u> – Agreed at December meeting to increase PR4 (Insufficient Financial Resources) risk rating from 16 to 20, this was endorsed in January's meeting. No change was proposed for PR8 (Sustainability) at a current risk rating of 12.

All papers were of a high quality and clear which helped the meeting run smoothly and promoted good constructive challenge and discussion.

Items recommended for consideration by other Committees

• None identified

Progress with Actions

Number of actions considered at the meeting – 13 (December) 14 (January) Number of actions closed at the meeting – 6 (December) 9 (January) Number of actions carried forward – 7 of which 4 are not yet due (December) 5 all of which are not yet due(January) Any concerns with progress of actions – No

Note: this report does not require a cover sheet due to sufficient information provided.